Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quality of life with Imiquimod 5% cream in actinic keratoses and superficial basal cell carcinoma
2008-002501-39Phase 4Active
- Sponsor
- Meda
- Start
- Oct 2008
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imiquimod in actinic keratosis (AK) and basal cell carcinoma (BCC), sponsored by Meda. Primary endpoint: Patient-reported quality of life during Imiquimod 5% self-treatment. Started Oct 2008; status: active.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2008-002501-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002501-39.